Viral vector-mediated gene therapy for opioid use disorders

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Opioid use disorder (OUD) is a complex CNS disease with limited treatment efficacy.
• Current pharmacotherapies like opioid maintenance therapy (OMT) have significant limitations and side effects.
• Developing novel, non-pharmacological treatments is crucial for improving OUD management.

Purpose of the Study:

• To review recent advancements in viral vector-mediated gene therapy for OUD.
• To highlight gene therapy's potential to restore neurotransmitter balance and mitigate OUD symptoms.
• To focus on gene therapy's application in addressing morphine tolerance and withdrawal.

Main Methods:

• Review of current literature on viral vector gene therapy for OUD in preclinical models.
• Focus on commonly used viral vectors: adenovirus (AV), adeno-associated virus (AAV), lentiviral (LV), and herpes simplex virus (HSV).
• Analysis of gene therapy's mechanism in targeting OUD's neurobiological underpinnings.

Main Results:

• Viral vector gene therapy demonstrates potential for targeted treatment of OUD.
• Gene therapy can restore neurotransmitter/neuropeptide balance, avoiding systemic drug side effects.
• Specific viral vectors show promise in preclinical models for OUD, including morphine tolerance and withdrawal.

Conclusions:

• Viral vector gene therapy presents a novel and potentially effective non-pharmacological strategy for OUD.
• This approach offers a way to directly address the neurobiological mechanisms of OUD.
• Further research into gene therapy holds promise for advancing OUD treatment options.